María Jones-Caballero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
María Jones-Caballero has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Pablo Fernández-Peñas
Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
14 shared publications Amaro García-Díez
6 shared publicationsJavier Fraga
5 shared publicationsEsteban Daudén
3 shared publicationsAmaro García-Diez
2 shared publicationsAmaro García‐Díez
From Ambulatorio Hermanos Sangro, Area 1 de Salud de Madrid, Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Catalan Institute of Public Health, Universitat de Barcelona, Barcelona, Spain, and Department of Dermatology, University of California and the San Francisco Veterans Affairs Hospital, San Francisco
2 shared publications
Latest Publications
- 25 October 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (8) , e248-e254
Real‐world data on the efficacy and safety of hedgehog pathway inhibitors in patients with basal cell carcinoma: Experience of a tertiary Australian centre
Background: Basal cell carcinomas (BCCs) are the most common cancers worldwide. Although most BCCs are amenable to local treatment, there are limited therapeutic options for surgically unresectable locally advanced and metastatic BCCs. Activation of the sonic hedgehog signalling pathway plays a significant role in the development of most BCCs. Hedgehog pathway inhibitors (HPIs) can be used to inhibit this pathway. Efficacy and safety data on HPI use in Australia is scarce.Objectives: This study aims to present the effectiveness and safety of HPI at a tertiary dermatology referral centre.Methods: We conducted a retrospective analysis of the clinical charts of all patients with BCC treated with an HPI at a tertiary Dermatology referral centre in New South Wales, Australia from 1 January 2016 to 1 July 2023.Results: Twenty‐three patients with BCCs were treated with an HPI; 11 locally advanced, 8 multiple, 3 basal cell naevus syndrome and 1 metastatic. All patients were of Caucasian background, with a median age of 56. Across 41 treatment cycles, the median treatment duration was 4 months. The overall response rate (ORR) was 20/23 (87%) and complete response (CR) rate was 9/23 (39%); patients treated with sonidegib achieved an ORR of 11/12 (92%) and CR of 4/12 (33%), and vismodegib‐treated patients achieved an ORR of 9/11 (82%) and CR of 5/11 (45%). Patients who responded to HPI treatment also responded to a subsequent HPI rechallenge. Common treatment emergent adverse events (TEAEs) included muscle spasms, dysgeusia and alopecia. Dysgeusia was more frequent with vismodegib than sonidegib (p = 0.0001). There was no evidence to suggest a difference in other TEAEs between the two HPIs. Four treatment cycles were stopped due to grade 3 muscle spasm.Conclusions: In our cohort of 23 patients being treated with HPI, the ORR was 87% and CR was 39%. All patients who experienced TEAEs and had a drug holiday successfully responded to HPI rechallenge. TEAEs, particularly muscle spasms, are common reasons for treatment cessation. Clinicians should implement strategies to mitigate TEAE to improve drug survivability.
- 25 October 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (8) , e248-e254
Real‐world data on the efficacy and safety of hedgehog pathway inhibitors in patients with basal cell carcinoma: Experience of a tertiary Australian centre
Background: Basal cell carcinomas (BCCs) are the most common cancers worldwide. Although most BCCs are amenable to local treatment, there are limited therapeutic options for surgically unresectable locally advanced and metastatic BCCs. Activation of the sonic hedgehog signalling pathway plays a significant role in the development of most BCCs. Hedgehog pathway inhibitors (HPIs) can be used to inhibit this pathway. Efficacy and safety data on HPI use in Australia is scarce.Objectives: This study aims to present the effectiveness and safety of HPI at a tertiary dermatology referral centre.Methods: We conducted a retrospective analysis of the clinical charts of all patients with BCC treated with an HPI at a tertiary Dermatology referral centre in New South Wales, Australia from 1 January 2016 to 1 July 2023.Results: Twenty‐three patients with BCCs were treated with an HPI; 11 locally advanced, 8 multiple, 3 basal cell naevus syndrome and 1 metastatic. All patients were of Caucasian background, with a median age of 56. Across 41 treatment cycles, the median treatment duration was 4 months. The overall response rate (ORR) was 20/23 (87%) and complete response (CR) rate was 9/23 (39%); patients treated with sonidegib achieved an ORR of 11/12 (92%) and CR of 4/12 (33%), and vismodegib‐treated patients achieved an ORR of 9/11 (82%) and CR of 5/11 (45%). Patients who responded to HPI treatment also responded to a subsequent HPI rechallenge. Common treatment emergent adverse events (TEAEs) included muscle spasms, dysgeusia and alopecia. Dysgeusia was more frequent with vismodegib than sonidegib (p = 0.0001). There was no evidence to suggest a difference in other TEAEs between the two HPIs. Four treatment cycles were stopped due to grade 3 muscle spasm.Conclusions: In our cohort of 23 patients being treated with HPI, the ORR was 87% and CR was 39%. All patients who experienced TEAEs and had a drug holiday successfully responded to HPI rechallenge. TEAEs, particularly muscle spasms, are common reasons for treatment cessation. Clinicians should implement strategies to mitigate TEAE to improve drug survivability.
- 1 October 2015
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (8) , 644-650
Quality of Life and Side Effects in Patients with Actinic Keratosis Treated With Ingenol Mebutate: A Pilot Study
- 1 October 2015
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (8) , 644-650
Quality of Life and Side Effects in Patients with Actinic Keratosis Treated With Ingenol Mebutate: A Pilot Study
- 7 June 2014
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 172 (1) , 160-168
A Spanish version of the skin cancer index: a questionnaire for measuring quality of life in patients with cervicofacial nonmelanoma skin cancer
Introduction The Skin Cancer Index (SCI) is the first specific patient‐reported outcome measure for patients with cervicofacial nonmelanoma skin cancer. To date, only the original English version has been published. Objectives To develop a Spanish version of the SCI that is semantically and linguistically equivalent to the original, and to evaluate its measurement properties in this different cultural environment. Material and methods A cross‐sectional study was conducted of the cultural adaptation and empirical validation of the questionnaire, analysing the psychometric properties of the new index at different stages. Results Of 440 patients recruited to the study, 431 (95%) completed the Spanish version of the SCI questionnaire, in a mean time of 6·3 min (SD 2·9). Factor analysis of the scale revealed commonality and loading values of < 0·5 for three of the 15 items. The remaining 12 items converged into two components: appearance/social aspects (seven items) and emotional aspects (five items). Both domains presented a high level of internal consistency, with Cronbach's alpha values above 0·8. The convergent–discriminant validity analysis produced correlations higher than 0·3 for the mental component of the Short Form Health Survey‐12v2 Health Questionnaire (correlation coefficient 0·39) and the Dermatology Quality of Life Index (correlation coefficient −0·30). In the test–retest, nine of the 12 items produced a weighted kappa value exceeding 0·4, and for the remaining three items, the absolute agreement percentage exceeded 60%. Conclusions The Spanish version of the SCI quality of life scale has been satisfactorily adapted and validated for use in Spanish‐speaking countries and populations.
- 7 June 2014
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 172 (1) , 160-168
A Spanish version of the skin cancer index: a questionnaire for measuring quality of life in patients with cervicofacial nonmelanoma skin cancer
Introduction The Skin Cancer Index (SCI) is the first specific patient‐reported outcome measure for patients with cervicofacial nonmelanoma skin cancer. To date, only the original English version has been published. Objectives To develop a Spanish version of the SCI that is semantically and linguistically equivalent to the original, and to evaluate its measurement properties in this different cultural environment. Material and methods A cross‐sectional study was conducted of the cultural adaptation and empirical validation of the questionnaire, analysing the psychometric properties of the new index at different stages. Results Of 440 patients recruited to the study, 431 (95%) completed the Spanish version of the SCI questionnaire, in a mean time of 6·3 min (SD 2·9). Factor analysis of the scale revealed commonality and loading values of < 0·5 for three of the 15 items. The remaining 12 items converged into two components: appearance/social aspects (seven items) and emotional aspects (five items). Both domains presented a high level of internal consistency, with Cronbach's alpha values above 0·8. The convergent–discriminant validity analysis produced correlations higher than 0·3 for the mental component of the Short Form Health Survey‐12v2 Health Questionnaire (correlation coefficient 0·39) and the Dermatology Quality of Life Index (correlation coefficient −0·30). In the test–retest, nine of the 12 items produced a weighted kappa value exceeding 0·4, and for the remaining three items, the absolute agreement percentage exceeded 60%. Conclusions The Spanish version of the SCI quality of life scale has been satisfactorily adapted and validated for use in Spanish‐speaking countries and populations.
- 27 March 2012
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 166 (4) , 884-887
Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis
Severity assessment of patients with psoriasis is a critical issue. Classical clinical assessment has recently been combined with quality of life (QoL) scores, but several instruments are used. Moreover, studies have focused on patients with moderate to severe psoriasis. To compare the characteristics of QoL instruments in patients with the full range of psoriasis severity attending dermatology clinics. Observational, prospective, multicentre study. Patients completed Skindex-29 (anchor) and a second instrument randomly selected from Dermatology Life Quality Index (DLQI), Psoriasis Disability Index (PDI) and Medical Outcome Study Short Form 36 (SF-36). Demographic data, Psoriasis Area and Severity Index and affected body surface area were not different between the three groups. Skindex-29 showed a weak but significant correlation with clinical severity; only PDI showed similar correlation. PDI, DLQI and SF-36 showed a substantial floor effect in patients with mild to severe psoriasis. Skindex-29 showed strong correlations with the other three QoL instruments. SF-36 was more sensitive than the other instruments in detecting worse QoL in male patients. Skindex-29 has better sensitivity to clinical severity with minimal floor effect, and covers the main domains explored by the other three QoL instruments in patients with mild to severe psoriasis.
- 27 March 2012
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 166 (4) , 884-887
Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis
Severity assessment of patients with psoriasis is a critical issue. Classical clinical assessment has recently been combined with quality of life (QoL) scores, but several instruments are used. Moreover, studies have focused on patients with moderate to severe psoriasis. To compare the characteristics of QoL instruments in patients with the full range of psoriasis severity attending dermatology clinics. Observational, prospective, multicentre study. Patients completed Skindex-29 (anchor) and a second instrument randomly selected from Dermatology Life Quality Index (DLQI), Psoriasis Disability Index (PDI) and Medical Outcome Study Short Form 36 (SF-36). Demographic data, Psoriasis Area and Severity Index and affected body surface area were not different between the three groups. Skindex-29 showed a weak but significant correlation with clinical severity; only PDI showed similar correlation. PDI, DLQI and SF-36 showed a substantial floor effect in patients with mild to severe psoriasis. Skindex-29 showed strong correlations with the other three QoL instruments. SF-36 was more sensitive than the other instruments in detecting worse QoL in male patients. Skindex-29 has better sensitivity to clinical severity with minimal floor effect, and covers the main domains explored by the other three QoL instruments in patients with mild to severe psoriasis.
- 20 August 2008
- Published by S. Karger AG in Dermatology
- Vol. 217 (4) , 309-314
Self-Reported Adherence to Treatment and Quality of Life in Mild to Moderate Acne
Background: Adherence to treatment is a mayor issue in dermatology, and its relationship to quality of life has barely been studied. Objective: To evaluate the relationship between scores on the Skindex-29 skin disease assessment scale and adherence to treatment in patients with acne. Methods: An observational, prospective study of 1,628 patients carried out by 252 clinicians in Spain. Results: Adherence was related to better objective and subjective severity index scores and better Skindex-29 scale scores at the end of the study. Young, male and unemployed patients had the worst adherence scores. Baseline and final Skindex-29 scale scores were significantly worse in non-adherent females, while non-adherent males scored better. Reasons for non-adherence were side effects for older patients and forgetfulness for younger ones. Conclusion: Dermatologists should explain that adherence to treatment is linked to better outcomes and better quality of life. Young females with high Skindex-29 scale scores and males with low Skindex scores are especially prone to non-adherence.
- 20 August 2008
- Published by S. Karger AG in Dermatology
- Vol. 217 (4) , 309-314
Self-Reported Adherence to Treatment and Quality of Life in Mild to Moderate Acne
Background: Adherence to treatment is a mayor issue in dermatology, and its relationship to quality of life has barely been studied. Objective: To evaluate the relationship between scores on the Skindex-29 skin disease assessment scale and adherence to treatment in patients with acne. Methods: An observational, prospective study of 1,628 patients carried out by 252 clinicians in Spain. Results: Adherence was related to better objective and subjective severity index scores and better Skindex-29 scale scores at the end of the study. Young, male and unemployed patients had the worst adherence scores. Baseline and final Skindex-29 scale scores were significantly worse in non-adherent females, while non-adherent males scored better. Reasons for non-adherence were side effects for older patients and forgetfulness for younger ones. Conclusion: Dermatologists should explain that adherence to treatment is linked to better outcomes and better quality of life. Young females with high Skindex-29 scale scores and males with low Skindex scores are especially prone to non-adherence.
- Open Access
- 1 July 2007
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 143 (7) , 846-850
Use of Biological Agents in Patients With Moderate to Severe Psoriasis
Research from JAMA Dermatology — Use of Biological Agents in Patients With Moderate to Severe Psoriasis — A Cohort-Based Perspective
- 1 July 2007
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 143 (7) , 846-850
Open AccessUse of Biological Agents in Patients With Moderate to Severe Psoriasis
Research from JAMA Dermatology — Use of Biological Agents in Patients With Moderate to Severe Psoriasis — A Cohort-Based Perspective
- 18 April 2007
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 21 (7) , 1005-1006
PUVA lentigines confined to mycosis fungoides lesions
- 18 April 2007
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 21 (7) , 1005-1006
PUVA lentigines confined to mycosis fungoides lesions
- Open Access
- 1 January 2007
- Published by Medical Journals Sweden AB
- Vol. 87 (2) , 176-177
Extranodal NK/T-Cell Lymphoma Nasal Type Mimicking Pyoderma Gangrenosum
- 1 January 2007
- Published by Medical Journals Sweden AB
- Vol. 87 (2) , 176-177
Open AccessExtranodal NK/T-Cell Lymphoma Nasal Type Mimicking Pyoderma Gangrenosum
- 20 December 2006
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 21 (2) , 219-226
Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment
Background Because of its effects on quality of life, acne vulgaris is more than a merely physiological or cosmetic entity.Objectives To describe the influence of mild to moderate acne on patients’ quality of life, measured using Skindex‐29, and to correlate changes in Skindex‐29 scores with changes in objective and subjective indices in clinical severity after treatment with topical 4% erythromycin 0.2% zinc. Also, to evaluate efficacy and side‐effects of the treatment.Methods Observational, prospective study of 1878 patients cared for by 252 clinicians in Spain. Data included epidemiological information and responses to Skindex‐29, a subjective change and objective severity index.Results Baseline Skindex scale scores were worse in women, older patients, and those with more severe clinical disease. Skindex was sensitive to changes in objective severity but changes in Skindex scale scores were also related to other factors. Patients who reported their skin condition to be ‘the same’ or ‘worse’ at the end of the study had significantly worse baseline scores on the ‘symptoms’ and ‘emotions’ scales but ‘functioning’ scores were not worse than for those who reported their condition had improved.Conclusion The effects of acne vulgaris on quality of life and changes in quality of life after treatment are not only explainable by objective severity of acne. Patients’ and clinicians’ judgements about acne severity are different.
- 20 December 2006
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 21 (2) , 219-226
Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment
Background Because of its effects on quality of life, acne vulgaris is more than a merely physiological or cosmetic entity.Objectives To describe the influence of mild to moderate acne on patients’ quality of life, measured using Skindex‐29, and to correlate changes in Skindex‐29 scores with changes in objective and subjective indices in clinical severity after treatment with topical 4% erythromycin 0.2% zinc. Also, to evaluate efficacy and side‐effects of the treatment.Methods Observational, prospective study of 1878 patients cared for by 252 clinicians in Spain. Data included epidemiological information and responses to Skindex‐29, a subjective change and objective severity index.Results Baseline Skindex scale scores were worse in women, older patients, and those with more severe clinical disease. Skindex was sensitive to changes in objective severity but changes in Skindex scale scores were also related to other factors. Patients who reported their skin condition to be ‘the same’ or ‘worse’ at the end of the study had significantly worse baseline scores on the ‘symptoms’ and ‘emotions’ scales but ‘functioning’ scores were not worse than for those who reported their condition had improved.Conclusion The effects of acne vulgaris on quality of life and changes in quality of life after treatment are not only explainable by objective severity of acne. Patients’ and clinicians’ judgements about acne severity are different.
- 1 October 2006
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 55 (4) , 729
The clinical and histologic spectrum of chronic graft-versus-host disease
- 1 October 2006
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 55 (4) , 729
The clinical and histologic spectrum of chronic graft-versus-host disease